Cadrenal Therapeutics and Abbott Collaborate to Advance Anticoagulant Tecarfarin for LVAD Patients
Cadrenal Therapeutics, Inc., a biopharmaceutical company, has announced a collaborative effort with Abbott to advance tecarfarin, a novel anticoagulant, for patients with recently implanted left ventricular assist devices (LVADs). LVAD patients require lifelong anticoagulation to protect against thromboembolic events.
Tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant, received FDA Orphan Drug Designation in April 2024 for the prevention of blood clots and strokes in patients with implanted mechanical circulatory support devices such as LVADs. The HeartMate 3™, manufactured by Abbott, is currently the only LVAD available in the United States and has demonstrated superiority over previous LVADs.
A recent secondary analysis of the ARIES-HM3 study conducted by Abbott highlighted the importance of maintaining high-quality anticoagulation in LVAD patients. The collaboration between Cadrenal Therapeutics and Abbott aims to further improve anticoagulation treatment for HeartMate 3 patients using tecarfarin.
Previous clinical studies have shown that tecarfarin can improve anticoagulation quality, particularly in LVAD patients who are on multiple medications or have impaired renal function. Tecarfarin has been evaluated in eleven human clinical trials involving over 1,000 individuals and has generally been well-tolerated.
Cadrenal Therapeutics is focused on developing tecarfarin to address unmet needs in anticoagulation therapy. The drug has orphan drug designation from the FDA for the prevention of thrombosis and thromboembolism in patients with implanted mechanical circulatory support devices, including LVADs. Tecarfarin also has orphan drug and fast-track designations for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease and atrial fibrillation.
The collaborative effort between Cadrenal Therapeutics and Abbott signifies an important step towards advancing anticoagulation treatment for LVAD patients. By leveraging tecarfarin’s potential to improve outcomes in patients with the HeartMate 3 LVAD, this collaboration aims to enhance the care and well-being of individuals with rare cardiovascular conditions.